All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is happy to present a Visual Abstract summarizing key data from the phase III QuANTUM-First trial, evaluating the addition of quizartinib vs placebo to standard chemotherapy and up to three years of continuation therapy in adults aged 18–75 with newly diagnosed FLT3-ITD+ acute myeloid leukemia (AML).
Download this visual abstract
Click here to download this visual abstractDownload
The QuANTUM-First trial
During the EHA 2022 Congress, the AML Hub was pleased to speak with Hee-Je Kim, The Catholic University of Korea, Seoul, KR, about the initial findings from the QuANTUM-First trial.
Editorial theme | An introduction to the use of transplantation for the treatment of AML
This article will look at the different stem cell sources used for HSCT, the patients selected for an HSCT, and the current major issues in the pre- and...
Subscribe to get the best content related to AML delivered to your inbox